The role of endothelin-1 in human hypertension

Clinical Hemorheology and Microcirculation

Volumn 37, Issue 1-2, 2007, Pages 157-178

  Shreenivas, Satya ^a   Oparil, Suzanne ^b,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (1,3 BENZODIOXOL 5 YL) 1 [(2,6 DIETHYLPHENYL)CARBAMOYLMETHYL] 2 (4 PROPOXYPHENYL) 3 PYRROLIDINECARBOXYLIC ACID; AMBRISENTAN; ATRASENTAN; BMS 207940; BOSENTAN; CLAZOSENTAN; DARUSENTAN; EDONENTAN; ENALAPRIL; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR; ENDOTHELIN B RECEPTOR ANTAGONIST; ENDOTHELIN RECEPTOR ANTAGONIST; ENRASENTAN; LU 208075; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; PLACEBO; SITAXSENTAN; SUCCINYLENDOTHELIN 1 [8-21][9 GLUTAMIC ACID 11,15 ALANINE]; TBC 3711; TEZOSENTAN; UNCLASSIFIED DRUG;

ACUTE HEART FAILURE; AFRICAN AMERICAN; BLOOD PRESSURE; BLOOD VESSEL TONE; CARDIOVASCULAR DISEASE; CAUCASIAN; CELL PROLIFERATION; CLINICAL TRIAL; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE EXACERBATION; DISEASE SEVERITY; DIZZINESS; DRUG INDUCED HEADACHE; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG TARGETING; ESSENTIAL HYPERTENSION; FLUSHING; GLOMERULONEPHRITIS; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART RATE; HEPATITIS; HEPATORENAL SYNDROME; HOMEOSTASIS; HUMAN; INOTROPISM; KIDNEY BLOOD VESSEL; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; KIDNEY MEDULLA; KIDNEY TUBULE CELL; LIVER TOXICITY; LOW DRUG DOSE; MESANGIUM CELL; NAUSEA; NONHUMAN; NOSE CONGESTION; PERIPHERAL EDEMA; PULMONARY HYPERTENSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIDE EFFECT; SUBARACHNOID HEMORRHAGE; SYSTOLIC BLOOD PRESSURE; THORAX PAIN; TREATMENT DURATION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION; VASODILATATION;

ANIMALS; ENDOTHELIN-1; HEART DISEASES; HUMANS; HYPERTENSION; KIDNEY TUBULES; RECEPTORS, ENDOTHELIN;

EID: 34347330354     PISSN: 13860291     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (114)

1. Z.A. Abassi, S. Ellahham, J. Winaver and A. Hofman, The intrarenal endothelin system and hypertension, News Physiol. Sci. 16 (2001), 52-56.
2. S. Abel-Sayed, J. Nussberger, J.F. Aubert, P. Gohlke, H.R. Brunner and N. Brakch, Measurement of plasma endothelin-1 in experimental hypertension and in healthy subjects, Am. J. Hypertension 16 (2003), 515-521.
3. D.J. Abraham, R. Vancheeswaran, M.R. Dashwood, V.S. Rajkumar, P. Pantelides, S.W. Xu, R.M. du Bois and C.M. Black, Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. Am. J. Pathol. 151 (1997), 831-841.
4. F. Amiri, A. Virdis, M.F. Neves, M. Iglarz, N.G. Seidah, R.M. Touyz, T.L. Reudelhuber and E.L. Schiffrin, Endothelium-restricted overexpression of human endothelin-1 causes vascular remodeling and endothelial dysfunction. Circulation, 110 (2004), 2233-2240.
5. K. Asano, T.J. Bohlmeyer, J.Y. Westcott, L.S. Zisman, K. Kinugawak, M. Good, W.A. Minobe, R. Roden, E.E. Wolfel, J. Lindenfeld, J.D. Port, M.B. Perryman, J. Clevel, B.D. Lowes and M.R. Bristow, Altered expression of endothelin in failing human ventricles, J. Mol. Cell. Cardiol. 34 (2002), 833-846.
6. R.J. Barst, S. Rich, A. Widlitz, E.M. Horn, V. Mclaughlin and J. McFarlin, Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: an open-label pilot study, Chest 121 (2002), 1860-1868.
7. M. Bauer, H. Wilkens, F. Langer, S.O. Schneider, H. Lausberg and H.J. Schafers, Selective upregulation of endothelin B receptor gene expression in severe pulmonary hypertension, Circulation 105 (2002), 1034-1036.
8. J. Bauersachs, D. Fraccarollo, P. Galuppo, J. Widder and G. Ertl, Endothelin-receptor blockade improves endothelial vasomotor dysfunction in heart failure, Cardiovasc. Res. 47 (2000), 142-149.
9. P.J.M. Best, C.J. McKenna, D. Hasdai, D.R.J. Holmes and A. Lerman, Chronic endothelin receptor antagonism preserves coronary endothelial function in experimental hypercholesterolaemia, Circulation 99 (1999), 1747-1752.
10. M. Browatzki, J. Schmidt, W. Kubler and R. Kranzhofer, Endothelin-1 induces interleukin-6 release via activation of the transcription factor NF-kappaB in human vascular smooth muscle cells, Basic Res. Cardiol. 95 (2000), 98-105.
11. F. Brunner, C. Bras-Silva, A.S. Cerdeira and A.F. Leite-Moreira, Cardiovascular endothelins: Essential regulators of cardiovascular homeostasis, Pharmacology and Therapeutics 111 (2006), 508-531.
12. F. Brunner and L.H. Poie, Role of endothelin-A receptors in ischemic contracture and reperfusion injury, Circulation 97 (1998), 391-398.
13. F. Brunner, Tissue endothelin-1 levels in perfused rat heart following stimulation with agonists and in ischemia and perfusion, J. Mol. Cell. Cardiol. 27 (1995), 1953-1963.
14. S.E. Burke, R.A. Nelson, N.L. Lubbers, T.T. Ford, I. Fuk, R.J. Padley, C.D. Wegner and B.F. Cox, Evidence for vasoconstriction mediated by the endothelin-B receptor in domestic swine, J. Cardiovasc. Pharmacol. 35 (2000), 838-844.
15. B. Buttistini, P. D'Orleans-Juste and P. Sirosis, Endothelins - circulating plasma levels and presence in other biologic fluids, Lab. Invest. 68 (1993), 600-628.
16. U. Campia, C. Cardillo and J.A. Panza, Ethnic differences in the vasoconstrictor activity of endogenous endothelin-1 in hypertensive patients, Circulation 109 (2004), 311-315.
17. C. Cardillo, U. Campia, C.M. Kilcoyne, M.B. Bryant and J.A. Panza, Improved endothelium-dependent vasodilation after blockade of endothelin receptors in patients with essential hypertension, Circulation 105 (2002), 452-456.
18. C. Cardillo, C.M. Kilcoyne, R.O. Cannon and J.A. Panza, Racial differences in nitric oxide-mediated vasodilator response to mental stress in the forearm circulation, Hypertension 31 (1998), 1235-1239.
19. 2+ signaling in contractile regulation induced by crosstalk between endothelin-1 and noepinephrine in dog ventricular myocardium, Circ. Res. 92 (2003), 1024-1032.
20. M. Clozel, Endothelin and endothelin receptors: The rationale for dual receptor antagonism, in: The Endothelin System in Cardiopulmonary Diseases, M. Clozel and L.J. Rubin, eds, Reinhardt Druck, Basil, 2005, pp.17-32.
21. P. D'Orleans-Juste, J. Labonte, G. Bkaily, S. Choufani, M. Plante and J.C. Honore, Function of the endothelin-B receptor in cardiovascular physiology and pathophysiology, Pharmacol. Ther. 95 (2002), 221-238.
22. A.P. Davenport, R.E. Kuc, J.J. Maguire and S.P. Harland, ET-A receptors predominate in the human vasculature and mediate constriction, J. Cardiovasc. Pharmacol. 26 (Suppl. 3) (1995), S265-S267.
23. G. Denucci, R. Thomas, P. D'Orleans-Juste, E. Antunes, C. Walder, T.D. Warner and J.R. Vane, Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor, Proc. Natl. Acad. Sci. USA 85 (1998), 9797-9800.
24. N. Dhaun, F.E. Strachan, D.E. Newby, N.R. Johnston, N.F. Ford, J.L. Hammett, M. Palmisano and D.J. Webb, Vasodilator effects of the endothelin ET-A receptor selective antagonist BMS-193884 in healthy men, Br. J. Clin. Pharmacol. 60 (2005), 611-622.
25. N. Dhuan, J. Goddard and D.F. Webb, The endothelin system and its antagonism in chronic kidney disease, J. Am. Soc. Nephrol. 17 (2006), 943-955.
26. J. Dupuis, C.A. Goresky and A. Fournier, Pulmonary clearance of circulating endothelin-1 in dogs in vivo: Exclusive role of ET-B receptors, J. Appl. Physiol. 81 (1996), 1510-1555.
27. R.M. Edwards, E.J. Stack, M. Pullen and P. Nambi, Endothelin inhibits vasopressin action in rat inner medullary collecting duct via the ETB receptor, J. Pharmacol. Exp. Therap. 267 (1993), 1028-1033.
28. F. Elijovich, C.L. Laffer, E. Amador, H. Gavras, M.R. Bresnahan and E.L. Schiffrin, Regulation of plasma endothelin by salt in salt-sensitive hypertension, Circulation 103 (2001), 263-268.
29. A. Ergul, Hypertension in black patients: An emerging role of the endothelin system in salt-sensitive hypertension, Hypertension 36 (2000), 62-67.
30. A. Ergul, R.L. Tackett and D. Puett, Distribution of endothelin receptors in saphenous veins of African-Americans: implications of racial differences, J. Cardiovasc. Pharmacol. 34 (1999), 327-332.
31. S. Ergul, C.D. Parish, D. Puett and A. Ergul, Racial differences in plasma endothelin-1 concentrations in individuals with essential hypertension, Hypertension 28 (1996), 652-655.
32. R.G. Evan, A.C. Madden, J.J. Oliver and T.V. Lewis, Effects of ET (A) and ET (B) receptor antagonists on regional kidney blood flow and responses to intravenous endothelin in anaesthetized rabbits, J. Hypertension 19 (2001), 1789-1799.
33. K. Fattinger, C. Funk, M. Pantze, C. Weber, J. Reichen, B. Stieger and P.J. Meier, The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: A potential mechanism for hepatic adverse reactions, Clin. Pharmacol. Ther. 69 (2001), 223-231.
34. M.I. Freed, D.E. Wilson, K.A. Thompson, R.Z. Harris, B.E. Ilson and D.K. Jorkasky, Pharmacokinetics and pharmacodynamics of SB209670, an endothelin receptor antagonist: Effects on the regulation of renal vascular tone, Clin. Pharmacol. Ther. 65 (1999), 473-482.
35. T. Fukuroda, T. Fujikawa, S. Ozaki, K. Ishikawa, M. Yano and M. Nishikibe, Clearance of circulating endothelin-1 by ET-B receptors in rats, Biophys. Res. Commun. 199 (1994), 1461-1465.
36. L. Galiuto, A.N. Demaria, U. del Balzo, K. May-Newman, S.F. Flaim, P.L. Wolf, M. Kirchengast and S. Iliceto, Ischemia reperfusion injury at the microvascular level - Treatment by endothelin-A selective antagonist and evaluation by myocardial contrast echocardiography, Circulation 102 (2000), 3111-3116.
37. N.H. Garcia and J.C. Gravin, Endothelin's biphasic effect on fluid absorption in the proximal straight tubule and its inhibitory cascade, J. Clin. Invest. 93 (1994), 2572-2577.
38. C.E. Gariepy, T. Ohuchi, S.C. William, J.A. Richardson and M. Yanagisawa, Salt-sensitive hypertension in endothelin-B receptor-deficient rats, J. Clin. Invest. 105 (2000), 925-933.
39. A. Garjani, C.L. Wainwright, I.J. Zeitlin, C. Wilson and S.J. Slee, Effects of endothelin-1 and the ET-A receptor antagonist BQ123 on ischemic arrhythmias in anesthetized rats, J. Cardiovasc. Pharmacol. 25 (1995), 634-642.
40. J. Goddard, C. Eckhart, N.R. Johnston, A.D. Cumming, A.J. Rankin and D.J. Webb, Endothelin A receptor antagonism and angiotensin-converting enzyme inhibition are synergistic via an endothelin B receptor-mediated and nitric oxide-dependent mechanism, J. Am. Soc. Nephrol. 15 (2004), 2601-2610.
41. J. Goddard, N.R. Johnston, M.F. Hand, A.D. Cumming, T.J. Rabelink, A.J. Rankin and D.J. Webb, Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: A comparison of selective and combined endothelin receptor blockade, Circulation 109 (2004), 1186-1193.
42. J. Gratton, G. Cournoyer, B.M. Loffler, P. Sirois and P. D'Orleans-Juste, ET-B receptor and nitric oxide synthase blockade induce BQ-123 sensitive pressor effect in the rabbit, Hypertension 30 (1997), 1204-1209.
43. K. Gurbanov, I. Rubinstein, A. Hoffman, Z. Abassi, O.S. Better and J. Winaver, Differential regulation of renal regional blood flow by endothelin-1, Am. J. Physiol. 271 (1996), F1166-F1172.
44. J.P. Halxoc, K.R. Nour, G. Zalos and A.A. Quyumi, Coronary vasodilation and improvement in endothelial dysfunction with endothelin ET(A) blockade, Circ. Res. 89 (2001), 969-976.
45. P.F. Harris, J. Zhou, F.A. Mendelsohn and S.L. Skinner, Haemodynamic and renal tubular effects of low doses of endothelin in anaesthetized rats, J. Physiol. 433 (1991), 25-39.
46. H. Hasegawa, K. Hiki, T. Sawamura, T. Aoyama, Y. Okamoto, S. Miwa, S. Shimohama, J. Kimura and T. Masaki, Purification of a novel endothelin- converting enzyme specific for big endothelin-3, FEBS Lett. 428 (1998), 304-308.
47. W.G. Hayes, C.J. Ferro, K.P. O'Kane, D. Somerville, C.C. Lomax and D.J. Webb, Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans, Circulation 93 (1996), 1860-1870.
48. M. Hiroe, Y. Hirata, N. Fujita, S. Umezawa, H. Ito, M. Tsujino, A. Koike, A. Nogami, T. Takamoto and F. Marumo, Plasma endothelin-1 levels in idiopathic dilated cardiomyopathy, Am. J. Cardiol. 68 (1991), 1114-1115.
49. A. Hoffman, Z.A. Abassi, S. Brodsky, R. Ramadan and J. Winaver, Mechanisms of big endothelin-1 induced diuresis and natriuresis: role of ET-B receptors, Hypertension 35 (2002), 732-736.
50. A. Hoffman, E. Grossman, D.S. Goldstein, J.F. Gill and H.R. Keiser, Urinary excretion rate of endothelin-1 in patients with essential hypertension and salt-sensitivity, Kidney Int. 45 (1994), 556-560.
51. J. Honore, M. Fecteau, I. Brocha, J. Labonte, G. Bkaily and P. D'Orleans-Juste, Concomitant antagonism of endothelial and vascular smooth muscle cell ET-B receptors for endothelin induces hypertension in the hamster, Am. J. Physiol. Heart Circ. Physiol. 289 (2005), H1258-H1264.
52. D. Hoyer, C. Waeber and T.M. Palacios, [125I] endothelin-1 binding sites: Autoradiographic studies in the brain and periphery of various species including humans, J. Cardiovasc. Pharmacol. 13 (Suppl 5) (1989), S162-S165.
53. A.K. Hughes, R.C. Cline and D.E. Kohan, Alterations in renal endothelin-1 production in the spontaneously hypertensive rat, Hypertension 20 (1992), 666-673.
54. T. Ikeda, H. Ohta, M. Okada, N. Kawai, R. Nakao, P.K.S. Siegl, T. Kobayashi, S. Maeda, T. Miyauchi and M. Nishikibe, Pathophysiological roles of endothelin-1 in Dahl salt-sensitive hypertension, Hypertension 34 (1999), 514-519.
55. W.E. Inscho, J.D. Imig, A.K. Cook and D.M. Pollock, ET (A) and ET (B) receptors differentially modulate afferent and efferent arteriolar responses to endothelin, Br. J. Pharmacol. 146 (2005), 1019-1026.
56. H.D. Intengan, G. He and E.L. Schiffrin, Effect of V1 vasopressin antagonism on small artery structure and vascular expression of preproendothelin-1 in DOCA-salt hypertensive rats, Hypertension 32 (1998), 770-777.
57. H.D. Intengan, J.B. Park and E.L. Schiffrin, Blood pressure and small arteries in DOCA-salt-treated genetically AVP-deficient rats: Role of endothelin, Hypertension 34 (1999), 907-913.
58. M. Kakoki, Y. Hirata, H. Hayakawa, A. Tojo, D. Nagata, E. Suzuki, K. Kimura, A. Goto, K. Kikuchi, T. Nagano and M. Omata, Effects of hypertension, diabetes mellitus, and hypercholesterolemia on endothelin type B receptor-mediated nitric oxide release from rat kidney, Circulation 99 (1999), 1242-1248.
59. P.R. Kalra, J.C. Moon and A.J. Coats, Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end of non-selective endothelin antagonism in heart failure? Int. J. Cardiol. 85 (2002), 195-197.
60. H. Krum, R.J. Viskoper, Y. Lacourciere, M. Budde and V. Charlon, for The Bosentan Hypertension Investigators, The effect of an endothelin-receptor antagonist bosentan on blood pressure in patients with essential hypertension, N. Engl. J. Med. 338 (1998), 784-790.
61. R. Kuc and A.P. Davenport, Comparison of endothelin-A and endothelin-B receptor distribution visualized by radioligand binding versus immunocytochemical localization using subtype selective antisera, J. Cardiovasc. Pharmacol. 44 (Suppl. 1) (2004), S224-S226.
62. R. Lariviere, J. St-Louis and E.L. Schiffrin, Vascular binding sites and biological activity of vasopressin in DOCA-salt hypertensive rats, Hypertension 6 (1988), 211-217.
63. M.E. Lee, M.S. Dhadly, D.H. Temizer, J.A. Clifford, M. Yoshizumi and T. Quertermous, Regulation of endothelin-1 gene expression by Fos and Jun, J. Biol. Chem. 266 (1991), 19034-19039.
64. A. Lerman, D.R. Holmes, M.R. Bell, K.N. Garratt, R.A. Nishimura and J.C. Burnett, Endothelin in coronary endothelial dysfunction and early atherosclerosis in humans, Circulation 92 (1995), 2426-2431.
65. J.S. Li, R. Lariviere and E.L. Schiffrin, Effect of a nonselective endothelin antagonist on vascular remodeling in deoxycorticosterone acetate-salt hypertensive rats: Evidence for a role of endothelin in vascular hypertrophy, Hypertension 24 (1994), 183-188.
66. T.F. Luscher, F. Enseleit, R. Pacher, V. Mitrovic, M.R. Schulze, R. Willenbrock, R. Dietz, V. Rousson, D. Hürlimann, S. Philipp, T. Notter, G. Noll and F. Ruschitzka, Hemodynamic and neurohumoral effects of selective endothelin-A receptor blockade in chronic heart failure: the Heart failure ET-A Receptor Blockade Trial (HEAT), Circulation 106 (2002), 2666-2672.
67. P.A. MacCarthy, R. Grocott-Mason, B.D. Prendergast and A.M. Shah, Contrasting inotropic effects of endogenous endothelin in the normal and failing human heart - Studies with an intracoronary ET-A receptor antagonist, Circulation 101 (2000), 142-147.
68. K.B. Margulies, F.L. Hildebrand, A. Lerman, M.A. Perrella and J.C. Burnett, Increased endothelin-1 in experimental heart failure, Circulation 82 (1990), 2226-2230.
69. B.A. Markewitz and D.E. Kohan, Role of intrarenal endothelin in the generation and maintenance of hypertension, Miner. Electrolyte Metab. 21 (1995), 342-352.
70. T. Masaki, Tissue specificity of the endothelin-induced responses, J. Cardiovasc. Pharmacol. 17 (Suppl. 7) (1991), S1-S4.
71. V. Mattew, D. Hasdai and A. Lerman, The role of endothelin in coronary atherosclerosis, Mayo Clin. Proc. 71 (1996), 769-777.
72. T. Miyauchi, M. Yanagisawa, T. Tomizawa, Y. Sugishita, N. Suzuki, M. Fujino, R. Ajisaka, K. Goto and T. Masaki, Increased plasma concentrations of endothelin-1 and big endothelin-1 in acute myocardial infarction, Lancet 2 (1989), 53-54.
73. A. Montanari, N. Carra, P. Perinotto, V. Iori, E. Fasoli, A. Biggi and A. Novarini, Renal hemodynamic control by endothelin and nitric oxide under angiotensin II blockade in man, Hypertension 39 (2002), 715-720.
74. P. Moreau, L.V. D'Uscio, S. Shaw, H. Takase, M. Barton and T.F. Luscher, Angiotensin II increases tissue endothelin and induces vascular hypertrophy: reversal by ETA-receptor antagonist, Circulation 96 (1997), 1593-1597.
75. S. Morita, K. Kitamura, Y. Yamomoto, T. Eto, Y. Osada, A. Sumiyoshi, M. Koono and K. Tanaka, Immunoreactive endothelin in human kidney, Ann. Clin. Biochem. 28 (1991), 267-271.
76. S. Motte, K. McEntee and R. Naeije, Endothelin receptor antagonists, Pharmacol. Ther. 110 (2006), 386-414.
77. Myogen reports positive results for Darusentan phase 2b trial in resistant hypertension, www.myogen.com (August 18, 2005).
78. S. Naicker and K.D. Bhoola, Endothelins: Vasoactive modulators of renal function in health and disease, Pharmac. Ther. 90 (2001), 61-88.
79. R. Nakov, E. Pfarr and S. Eberle, Darusentan: An effective endothelin-A receptor antagonist for treatment of hypertension, Am. J. Hypertens. 15 (2002), 583-589.
80. T. Neunteufl, R. Berger and R. Pacher, Endothelin receptor antagonists in cardiology clinical trials, Expert. Opin. Investig. 11 (2002), 431-443.
81. T. Omland, R.T. Lie, A. Aakvaag, T. Arsland and K. Dickstein, Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction, Circulation 89 (1994), 1573-1579.
82. A.C. Ong, T.P. Joweff, J.D. Firth, S. Burton, M. Kitamura and L.G. Fine, Human tubular-derived endothelin in the paracrine regulation of renal interstitial fibroblast function, Exp. Nephrol. 2 (1994), 134.
83. M.C. Ortiz, M.C. Manriquez, J.C. Romero and L.A. Juncos, Antioxidants block angiotensin II-induced increases in blood pressure and endothelin, Hypertension 38 (2001), 655-659.
84. M. Packer, J. McMurray, B.M. Massie, A. Caspi, V. Charlon, A. Cohen-Solal, W. Kiowski, W. Kostuk, H. Krum, B. Levine, P. Rizzon, J. Soler, K. Swedberg, S. Anderson and D.L. Demets, Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study, J. Card. Fail. 11 (2005), 12-20.
85. J. Pernow, A. Franco-Cereceda, R. Matran and J.M. Lundberg, Effect of endothelin-1 on regional vascular resistance in the pig, J. Cardiovasc. Pharmacol. 13 (Suppl. 16) (1989), S205-S206.
86. J. Pernow and Q.D. Wang, Endothelin in myocardial ischemia and reperfusion, Cardiovasc. Res. 33 (1997), 518-526.
87. B. Pieske, B. Beyermann, V. Breu, B.M. Loffler, K. Schlotthauer, L.S. Maier, S. Schmidt-Schweda, H. Just and G. Hasenfuss, Functional effects of endothelin and regulation of endothelin receptors in isolated human nonfailing and failing myocardium, Circulation 99 (1999), 1802-1809.
88. C.F. Plato, B.A. Stoos, D. Wang and J.L. Gorvin, Endogenous nitric oxide inhibits chloride transport in the thick ascending limb, Am. J. Physiol. 276 (1999), F159-F163.
89. S. Rajagopalan, J.B. Laursen, A. Borthayre, S. Kurz, J. Keiser, S. Haleen, A. Giaid and D.G. Harrison, Role of endothelin-1 in angiotensin II-mediated hypertension, Hypertension 30 (1997), 29-34.
90. T.J. Rubelink, K.A.H. Kaasjager, P. Boer, E.G. Stroes, B. Braam and H.A. Koomans, Effects of endothelin-1 on renal function in humans: Implications for physiology and pathophysiology, Kidney Int. 46 (1994), 376-381.
91. I. Rubinstein, K. Gurbanov, A. Hoffman, O.S. Better and J. Winaver, Differential effect of endothelin-1 on renal regional blood flow: Role of nitric oxide, J. Cardiovasc. Pharmacol. 26 (1995), S208-S210.
92. S.D. Russell, J.N. Skepper and A.P. Davenport, Detection of endothelin receptors in human coronary artery vascular smooth muscle cells but not endothelial cells by using electron microscope autoradiography, J. Cardiovasc. Pharmacol. 29 (1997), 820-826.
93. S. Sakai, T. Miyauchi, M. Kobayashi, I. Ymaguchi, K. Goto and Y. Sugishita, Inhibition of myocardial endothelin pathway improves long-term survival in heart failure, Nature 384 (1996), 353-355.
94. E. Schiffrin, Vascular endothelin in hypertension, Vasc. Pharmacol. 43 (2005), 19-29.
95. E.L. Schiffrin, Role of endothelin in hypertension, Hypertension 34 (1999), 876-881.
96. L. Schmetter, S. Dallinger, B. Bobr, N. Selenko, H.-G. Eichler and M. Woltz, Systemic and renal effects of an ETA receptor subtype-specific antagonist in healthy subjects, Br. J. Pharmacol. 124 (1998), 930-934.
97. G. Stawski, U.B. Olsen and P. Grande, Cytotoxic effect of endothelin-1 during "stimulated" ischemia in cultured myocytes, Eur. J. Pharmacol. 201 (1991), 123-124.
98. E.F. Strachan, J.C. Sprat, I.B. Wilkinson, N.R. Johnston, G.A. Gray and D.J. Webb, Systemic blockade of the endothelin-B peripheral vascular resistance in healthy men, Hypertension 33 (1999), 581-585.
99. G. Sutsch, O. Bertel and W. Kiowsi, Acute and short-term effects of the nonpeptide endothelin-1 receptor antagonist bosentan in humans, Cardiovasc. Drugs. Ther. 10 (1996), 717-725.
100. N. Suzuki, T. Miyauchi, Y. Tomobe, H. Matsumoto, K. Goto, T. Masaki and M. Fujino, Plasma concentrations of endothelin-1 in spontaneously hypertensive rats and DOCA-salt hypertensive rats, Biochem. Biophys. Res. Commun. 167 (1990), 941-947.
101. K.A. Treinen, C. Louden, M.J. Dennis and P.J. Weir, Developmental toxicity and toxicokinetics of two endothelin receptor antagonists in rats and rabbits, Teratology 59 (1999), 51-59.
102. H. Tsukahasa, H. Ende, H.I. Magazine, W.F. Bahou and M.S. Goligorsky, Molecular and functional characterization of the non-isopeptide-selective ET-B receptor in endothelial cells: receptor coupling to nitric oxide synthase, J. Biol. Chem. 269 (1994), 21778-21785.
103. M.C. Verhaar, F.E. Strachan, D.E. Newby, N.L. Cruden, H.A. Koomans, T.J. Rabelink and D.J. Webb, Endothelin-A receptor antagonist mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade, Circulation 97 (1998), 752-756.
104. C. Villar, C.J.G. Alonso, C.A. Feldstein, L.A. Juncos and J.C. Romero, Role of endothelin in the pathogenesis of hypertension, Mayo Clinic. Proc. 80 (2005), 84-96.
105. G. Vorobiof, B.C. Blaxall and J.D. Bisognano, The future of endothelin receptor antagonism as treatment for systemic hypertension, Current Hypertension Reports 8 (2006), 35-44.
106. T.J. Vuurmans, P. Boer and H.A. Koomans, Effects of endothelin-1 and endothelin-1 receptor blockade on cardiac output, aortic pressure, and pulse wave velocity in humans, Hypertension 41 (2003), 1253-1258.
107. O.F. Wagner, G. Crist, J. Wojta, H. Vierhapper, S. Parzer, P.J. Nowotny, B. Schneider, W. Waldhausl and B.R. Binder, Polar secretion of endothelin-1 by cultured endothelial cells, J. Biol. Chem. 267 (1992), 16066-16068.
108. C. Weber, R. Schmitt, H. Birnboeck, G. Hopfgartner, S.P. van Marle, P.A. Peeters, J.H. Jonkman and C.R. Jones, Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects, Clin. Pharmacol. Ther. 60 (1996), 124-137.
109. S. Wedgwood, R.W. Dettman and S.M. Black, ET-1 stimulates pulmonary arterial smooth muscle cell proliferation via induction of reactive oxygen species, Am. J. Physiol. Lung. Cell. Mol. Physiol. 281 (2001), L1058-L1067.
110. C.M. Wie, A. Lerman, R.J. Rodeheffer, C.G.A. McGregor, R.R. Brandt, S. Wright, D.M. Heublein, P.C. Kao, W.D. Edwards and J.C. Burnett, Endothelin in human congestive heart failure, Circulation 89 (1994), 1580-1586.
111. N.L. Wong, M. Sonntag and J.K. Tsui, Attenuation of renal vasopressin V2 receptor upregulation by bosentan, an EtA/ETB receptor antagonist, Metabolism 52 (2003), 1141-1146.
112. M. Yanagisawa, H. Kurihara, S. Kimura, Y. Tomobe, M. Kobayashi, Y. Mitsui, Y. Yazaki, K. Goto and T. Masaki, A novel potent vasoconstrictor peptide produced by vascular endothelial cells, Nature 332 (1988), 411-415.
113. S. Yoshimoto, Y. Ishizaki, T. Sasaki and S. Murota, Effect of carbon dioxide and oxygen on endothelin production by cultured porcine cerebral endothelial cells, Stroke 22 (1991), 378-383.
114. C. Zoccali, D. Leonardis, S. Parlongo, F. Mallamaci and M. Postorino, Urinary and plasma endothelin-1 in essential hypertension and in hypertension secondary to renoparenchymal disease, Nephrol. Dial. Transplant. 10 (1995), 1320-1323.